Harm potential of magic mushroom use: A review

Regulatory Toxicology and Pharmacology

Volumn 59, Issue 3, 2011, Pages 423-429

  Amsterdam, Jan van ^a   Opperhuizen, Antoon ^a   Brink, Wim van den ^b,c  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c AMSTERDAM INSTITUTE FOR ADDICTION RESEARCH   (Netherlands)

Author keywords

Adverse effects; Illicit drugs; Magic mushrooms; Recreational drugs; Risk assessment

Indexed keywords

ALCOHOL; PSILOCIN; PSILOCYBINE;

ABDOMINAL PAIN; ACUTE TOXICITY; ALCOHOL CONSUMPTION; ANXIETY; ARTICLE; CHRONIC TOXICITY; CRIMINAL BEHAVIOR; DIZZINESS; DRUG DEPENDENCE; HALLUCINATION; HAZARD ASSESSMENT; HEALTH HAZARD; HUMAN; INTOXICATION; MORTALITY; MUSHROOM; MYALGIA; MYDRIASIS; NAUSEA; NETHERLANDS; PANIC; PARANOIA; PRIORITY JOURNAL; PSYCHOSIS; SAFETY; SHIVERING; SUICIDE ATTEMPT; WEAKNESS;

ACCIDENTS; AGARICALES; ANIMALS; HALLUCINOGENS; HUMANS; NETHERLANDS; PANIC DISORDER; PSYCHOSES, SUBSTANCE-INDUCED; RISK ASSESSMENT; SUBSTANCE-RELATED DISORDERS;

BASIDIOMYCOTA; PSILOCYBE CUBENSIS;

EID: 79952693734     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2011.01.006     Document Type: Article

References (69)

1. Abraham H.D., Aldridge A.M., Gogia P. The psychopharmacology of hallucinogens. Neuropsychopharmacology 1996, 14:285-298.
2. Abraham M.D., Kaal H.L., Cohen P.D.A. Licit and illicit drug use in the Netherlands 2001 2002, CEDRO/Mets en Schilt, Amsterdam.
3. Abramson H.A., Rolo A. Lysergic acid diethylamide (LSD-25). 38. Comparison with action of methysergide and psilocybin on test subjects. J. Asthma Res. 1965, 3:81-96.
4. Allen J.W. A private inquiry into the circumstances surrounding the 1972 death of John Gomilla, Jr., who died after allegedly consuming ten hallucinogenic mushrooms while residing in Hawaii. J. Psychoact. Drugs 1988, 20:451-454.
5. Allen J.W., Merlin M.D., Jansen K.L. An ethnomycological review of psychoactive agarics in Australia and New Zealand. J. Psychoact. Drugs 1991, 23:39-69.
6. Anthony J.C., Warner L.A., Kessler R.C. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp. Clin. Psychopharmacol. 1994, 2:244-268.
7. Asselborn G., Wennig R., Yegles M. Tragic Flying Attempt Under the Influence of "Magic Mushrooms" Laboratoire National de Santé, Division Toxicologie, CRP-Santé 1999, Centre Universitaire, Luxembourg.
8. Beck O., Helander A., Karlson-Stiber C., Stephansson N. Presence of phenylethylamine in hallucinogenic psilocybe mushroom: possible role in adverse reactions. J. Anal. Toxicol. 1998, 22:45-49.
9. Benjamin C. Persistent psychiatric symptoms after eating psilocybin mushrooms. Br. Med. J. 1979, 1:1319-1320.
10. Black Poppy., 2006. The Fly Agaric Mushroom, Black Poppy: a drug users health and lifestyle magazine, issue 11. Website: (retrieved November 2010). http://www.blackpoppy.org.uk/science_flyargaric.html.
11. Bosch, J.A., Pennings, E.J.M., de Wolff, F.A., 1997. Psychoactieve paddestoel and plantproducten; toxicologie en klinische effecten. Report to the Ministry of Health.
12. Bück R.W. Mushroom poisoning since 1924 in United States. Mycologia 1961, 53:537-538.
13. Buster, M, van Brussel, G., 2007. Acute medische hulp in verband met incidenten door het gebruik van roesmiddelen in Amsterdam, 2007. Een stijgende trend van paddo-incidenten. GG&GD Amsterdam (Amsterdam Municipal Health Service). Website: (retrieved November 2010). http://www.gezond.amsterdam.nl.
14. CAM., 2000. Risk Assessment report relating to paddos (psilocin and psilocybin). Coordination Centre for the Assessment and Monitoring of New Drugs (CAM), Den Haag, The Netherlands. Website: (retrieved November 2010). http://www.rivm.nl/bibliotheek.
15. CAM. 2007. Report of Coordination point Assessment and Monitoring new drugs (CAM). Aanvullende informatie paddoincidenten in Amsterdam. Website: (retrieved November 2010). http://www.rivm.nl/bibliotheek.
16. Carhart-Harris R.L., Nutt D.J. User perceptions of the benefits and harms of hallucinogenic drug use: a web-based questionnaire study. J. Subst. Abuse 2010, 15:283-300.
17. Carter O.L., Pettigrew J.D., Hasler F., Wallis G.M., Liu G.B., Hell D., Vollenweider F.X. Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin. Neuropsychopharmacology 2005, 30:1154-1162.
18. Curry S.C., Rose M.C. Intravenous mushroom poisoning. Ann. Emerg. Med. 1985, 14:900-902.
19. De Gelderlander. 2-10-2008. Website: (retrieved November 2010). http://www.gelderlander.nl.
20. De Telegraaf. 3-8-2008. Website: (retrieved November 2010). http://www.telegraaf.nl/binnenland.
21. Erowid., 2006. Erowid. Website: Dated: 25.03.2006. http://www.erowid.org.
22. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Hallucinogenic mushrooms: an emerging trend case study. Website: (retrieved November 2010). http://www.emcdda.europa.eu.
23. Expatica Communications B.V., 2008. Retrieved November 2010. http://www.expatica.com/nl/news.
24. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., MacGregor R., Alexoff D., Shea C., Schlyer D., Wolf A.P., Warner D., Zezulkova I., Cilento R. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996, 379:733-736.
25. Gerault, A, Picart, D., 1996. Intoxication mortelle a la suite de la consommation volontaire et en groupe de champignons hallucinogenes [Fatal Poisoning After a Group of People Voluntarily Consumed Hallucinogenic Mushrooms]. Bull. Soc. Mycol. Franc 112, 1-14. Website: (retrieved January 2011). http://www.lycaeum.org.
26. Gonmori K., Yoshioka N. Fatal Ingestion of magic mushroom: a case report. Ann. Toxicol. Anal. 2002, 14:350.
27. Gouzoulis-Mayfrank E., Heekeren K., Thelen B., Lindenblatt H., Kovar K.A., Sass H., Geyer M.A. Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Behav. Pharmacol. 1998, 9:561-566.
28. Gouzoulis-Mayfrank E., Thelen B., Habermeyer E., Kunert H.J., Kovar K.A., Lindenblatt H., Hermle L., Spitzer M., Sass H. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology (Berl) 1999, 142:41-50.
29. Griffiths R.R., Richards W.A., McCann U., Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 2006, 187:268-283.
30. Halpern J.H., Pope H.-G.J. Do hallucinogens cause residual neuropsychological toxicity?. Drug Alcohol Depend. 1999, 53:247-256.
31. Halpern J.H., Pope H.-G.J. Hallucinogen persisting perception disorder: what do we know after 50years?. Drug Alcohol Depend. 2003, 69:109-119.
32. Hasler F., Grimberg U., Benz M.A., Huber T., Vollenweider F.X. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl) 2004, 172:145-156.
33. Hibell, B, Andersson, B, Bjarnasson, T, Ahlström, S, Balakivari, O, Kokevi, A, Morgan, M., 2003. The 2003 ESPAD Report; Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm. Website: http://www.sedqa.gov.mt.
34. Isbell H., Wolbach A.B., Wikler A., Miner E.J. Cross tolerance between LSD and psilocybin. Psychopharmacologia 1961, 2:147-159.
35. Jacob, M.R., Fehr, K.O.B., 1987. Drugs and drug abuse: a reference text, second ed. Toronto, Addiction Research Foundation, quoted through Neuroscience of psychoactive substance use and dependence, (2004) WHO, Geneva: pp. 104-105.
36. KLPD. 2007. Briefing J. van der Klein, N. de Bruin, Korps Landelijke Politiediensten, May 2007.
37. Korf, D.J., Nabben, T., 2007. Briefing of Bongers Institute, University of Amsterdam.
38. Kresanek J., Plackova S., Caganova B., Klobusicka Z. Drug abuse in Slovak Republic. Przegl. Lek. 2005, 62:357-360.
39. Leary T., Litwin G.H., Metzner R. Reactions to psilocybin administered in a supportive environment. J. Nerv. Mental Dis. 1963, 137:561-573.
40. Levitt, R, Nason, E, Hallsworth, M., 2006. The Rand Corporation. The evidence base for the classification of drugs. Website: (retrieved November 2010). http://www.rand.org/pubs.
41. Mccawley E.L., Brummett R.E., Dana G.W. Convulsions from psilocybe mushroom poisoning. Proc. West. Pharmacol. Soc. 1962, 5:27-33.
42. Metzner R., Litwin G.H., Weil G.M. The relation of expectation and mood to psilocybin reactions: a questionnaire study. Psychedelic Rev. 1965, 5:339.
43. Mixmag., 2005. Mixmag Drug Survey 2000-2005 - evidence includes personal communication from Dr. Luke Mitcheson. Reference cited in EMCDDA report. Website: (retrieved November 2010). http://www.emcdda.europa.eu.
44. Monshouwer, K, Dorsselaer, S, Gorter, A, Verdurmen, J., Vollebergh, W., 2004. Jeugd en riskant gedrag; kerngegevens uit het peilstationsonderzoek 2003. Trimbos instituut Utrecht.
45. NFI 2007. Personal communication. Briefing by Nederlands Forensic Instituut (NFI; Dutch Forensic Institute). May 2007.
46. Nielen R.J., van der Heijden F.M., Tuinier S., Verhoeven W.M. Khat and mushrooms associated with psychosis. World J. Biol. Psychiatry 2004, 5:49-53.
47. Nordic Council of Ministers 2009. Occurrence and use of hallucinogenic mushrooms containing psilocybin alkaloids. Copenhagen. Website: (retrieved November 2010). http://www.norden.org.
48. Nutt D.J., King L.A., Saulsbury W., Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007, 369:1047-1053.
49. Nutt D.J., King L.A., Phillips L.D. Drug harms in the UK: a multicriteria decision analysis. Lancet 2010, 376:1558-1565.
50. O'Brien, CP., 1996. Drug addiction and drug abuse. In: Hardman, J.J., Limbird, L. (Ed.), Goodman and Guilman's the pharmacological basis of therapeutics, ninth ed., pp. 557-577.
51. Pechnick, R.N., Ungerleider, J.T., 2005. Hallucinogens, In: Lowinson, J. H., Ruiz, P., Millman, R. B., Langrod, J. G. (Ed.), Substance Abuse A Comprehensive Textbook, fourth ed. pp. 313-323.
52. Quetin, A.M., 1960. La psilocybine en psychiatrie clinique et experimentale. Paris: Medical dissertation.
53. Riley S.C., Blackman G. Between prohibitions: patterns and meanings of magic mushroom use in the UK. Subst. Use Misuse 2008, 43:55-71.
54. Roe, S., 2005. Drug Misuse Declared: findings from the 2004/05 British Crime Survey, HOSB 16/05 (London: Home Office). Website: (retrieved November 2010). http://rds.homeoffice.gov.uk.
55. Satora L., Goszcz H., Ciszowski K. Poisonings resulting from the ingestion of magic mushrooms in Krakow. Przegl. Lek. 2005, 62:394-396.
56. Shroomery. 2007. The Shroomery - http://www.shroomery.org.
57. Sivyer G., Dorrington L. Intravenous injection of mushrooms. Med. J. Aust. 1984, 140:182.
58. Stone A.L., O'Brien M.S., De La Torre A., Anthony J.C. Who is becoming hallucinogen dependent soon after hallucinogen use starts?. Drug Alcohol Depend. 2007, 87:153-163.
59. Stone A.L., Storr C.L., Anthony J.C. Evidence for a hallucinogen dependence syndrome developing soon after onset of hallucinogen use during adolescence. Int. J. Methods Psychiatr. Res. 2006, 15:116-130.
60. Studerus E., Kometer M., Hasler F., Vollenweider F.X. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J. Psychopharmacol. 2010, 10.1177/0269881110382466.
61. Trimbos., 2010. Monitor drugsincidenten. Fact sheet 2009. Website: (retrieved November 2010). http://www.drugsincidenten.nl.
62. van Amsterdam J.G.C., Opperhuizen A., Koeter M., van den Brink W. Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. Eur. Addict. Res. 2010, 16:202-207.
63. van Amsterdam J.G.C., Talhout R., Vleeming W., Opperhuizen A. Contribution of monoamine oxidase (MAO) inhibition to tobacco and alcohol addiction. Life Sci. 2006, 79:1969-1973.
64. van Amsterdam J.G.C., van de Brink W. Cannabis als risicofactor van schizofrenie. Tijdschr. Psychologie 2004, 46:515-524.
65. Vollenweider F.X., Geyer M.A. A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res. Bull. 2001, 56:495-507.
66. Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F., Babler A., Vogel H., Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998, 9:3897-3902.
67. VWA 2007. Briefing of VWA (Dutch Food and Consumer Product Safety Authority).
68. Wittmann M., Carter O., Hasler F., Cahn B.R., Grimberg U., Spring P., Hell D., Flohr H., Vollenweider F.X. Effects of psilocybin on time perception and temporal control of behaviour in humans. J. Psychopharmacol. 2007, 21:50-64.
69. Zinberg N.A. Drug, Set, and Setting: The Basis for Controlled Intoxicant Use 2010, Yale University Press, London.